Cardiovascular Outcomes of Semaglutide and Tirzepatide in Type 2 Diabetes
- Recent cardiovascular outcome trials have indicated that incretin-based medications, specifically tirzepatide and semaglutide, offer cardiovascular benefits to individuals with varying degrees of cardiovascular risk.
- The study design initially emulated two pivotal cardiovascular outcome trials - SUSTAIN-6 (semaglutide versus sitagliptin) and SURPASS-CVOT (tirzepatide versus dulaglutide) - to validate the research methodology, data quality,...
- Analysis of expanded patient populations revealed a hazard ratio of 0.82 (95% Confidence Interval: 0.74 to 0.91) when comparing semaglutide to sitagliptin for a composite outcome of myocardial...
Real-World Evidence Supports Cardiovascular Benefits of Tirzepatide and Semaglutide
Table of Contents
Published November 10, 2025
study Background and Objectives
Recent cardiovascular outcome trials have indicated that incretin-based medications, specifically tirzepatide and semaglutide, offer cardiovascular benefits to individuals with varying degrees of cardiovascular risk. Tho, a direct comparison between the two drugs has been lacking, leading to uncertainty in treatment decisions. Researchers conducted five cohort studies between 2018 and 2025, analyzing data from United States insurance programs to evaluate the effectiveness of both medications in patients with elevated cardiovascular risk, including those with obesity and type 2 diabetes.
Methodology: Emulating Landmark Trials
The study design initially emulated two pivotal cardiovascular outcome trials – SUSTAIN-6 (semaglutide versus sitagliptin) and SURPASS-CVOT (tirzepatide versus dulaglutide) – to validate the research methodology, data quality, and analytical framework. This benchmarking process aimed to ensure the real-world evidence findings were comparable to those established in controlled clinical trials. Propensity score matching was used to balance baseline characteristics among patient groups, minimizing confounding factors.
Key Findings: Expanded Populations
Analysis of expanded patient populations revealed a hazard ratio of 0.82 (95% Confidence Interval: 0.74 to 0.91) when comparing semaglutide to sitagliptin for a composite outcome of myocardial infarction or stroke. Similarly, tirzepatide demonstrated a hazard ratio of 0.87 (0.75 to 1.01) compared to dulaglutide for a composite outcome including all-cause mortality.
Head-to-Head Comparison: Tirzepatide vs. Semaglutide
A direct comparison of tirzepatide and semaglutide showed a hazard ratio of 1.06 (0.95 to 1.18) for the composite endpoint of myocardial infarction, stroke, or all-cause mortality. While this result wasn’t statistically significant, it suggests comparable cardiovascular benefits between the two medications in a real-world clinical setting.
Implications and Future Research
These findings reinforce the cardiovascular benefits of both tirzepatide and semaglutide when used in routine clinical practice. The study highlights the value of rigorously designed real-world evidence studies in complementing data from randomized controlled trials, providing a more extensive understanding of drug effectiveness in diverse patient populations. This approach can help inform treatment decisions and optimize patient care.